<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/a79913bb-5354-496c-911d-2f8215cad958/ryan-board-room-b.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="2752" height="1664" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/a79913bb-5354-496c-911d-2f8215cad958/ryan-board-room-b.png"/></p>
<p>新澤西州沃倫，2025 年 12 月 22 日（GLOBE NEWSWIRE）—— Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（納斯達克：TVGN）今天宣佈，其創始人兼首席執行官 Ryan Saadi 博士向 SRLC USA 捐贈了 230,000 股 Tevogen 普通股，該組織是一個獲得聯合國認可的 501(c)(3) 非營利組織，致力於服務弱勢社區。</p>
<p>“教育是我們在建設更健康、更公平的社會中可以進行的最有力的長期投資之一，” Saadi 博士説。“我很高興能夠支持一個致力於通過有意義、可衡量的行動來提升弱勢社區的組織。”</p>
<p>此次捐贈是根據 SEC 第 144 條規則進行的，Saadi 博士將不會從證券處置中獲得任何收益。</p>
<p><strong>關於 Tevogen</strong></p>
<p>Tevogen 是一家基於可負擔性、效率和科學嚴謹原則構建的下一代社會整合醫療企業。該公司利用行業領先的人工智能和精準 T 細胞治療平台，以患者為中心並注重成本的運營模式，以及與全球技術領導者的戰略合作，支持在多個治療領域開發先進的、拯救生命的療法和可擴展的解決方案，以改善更廣泛的醫療保健系統。</p>
<p>Tevogen Bio 是公司的主要項目，已完成一項概念驗證臨牀試驗，展示了其單 HLA 限制、基因未修飾的異體 T 細胞的潛力。Tevogen Bio 的產品線涵蓋病毒學、腫瘤學和神經學，基於公司的專有 ExacTcell™平台構建。</p>
<p>Tevogen.AI 旨在通過加速靶點檢測、幫助降低失敗率以及通過專有預測技術支持優化臨牀試驗設計來改變藥物開發。該平台利用來自領先技術提供商（包括微軟和 Databricks）的雲和數據服務，以推進其長期目標，即預測任何給定蛋白質-HLA 組合的蛋白質組，從而實現快速且成本高效的治療發現。</p>
<p>Tevogen 正在探索未來的戰略舉措，可能包括國內仿製藥、生物類似藥、醫療設備和創新保險解決方案，以服務醫療提供者。這些項目共同反映了 Tevogen 的使命，即通過更快、更高效和更公平的醫療模式推動可持續創新，擴大患者的獲取渠道。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含某些前瞻性聲明，包括但不限於與 Tevogen 的研究和製造能力的計劃、未來增長的預期、對醫療保健和生物製藥行業的預期，以及 Tevogen 對其產品候選者在治療傳染病和癌症方面的開發、潛在益處和患者獲取的預期。前瞻性聲明有時可以通過 “可能”、“可以”、“將”、“期望”、“預期”、“可能”、“潛在”、“目標”、“機會”、“項目”、“相信”、“未來” 等詞語及其反義詞來識別。這些聲明基於管理層截至本新聞稿日期的期望、假設、估計、預測和信念，並受到多種因素的影響，這些因素涉及已知和未知的風險、延遲、不確定性以及其他不在公司控制範圍內的因素，可能導致公司的實際結果、表現或成就與這些前瞻性聲明所表達或暗示的結果、表現或其他期望存在重大差異。</p>
<p>可能導致實際結果、表現或成就與前瞻性聲明所表達或暗示的結果存在差異的因素包括但不限於：Tevogen 所競爭市場的變化，包括其競爭格局、技術演變或監管變化；國內和全球經濟狀況的變化；Tevogen 可能無法執行其增長戰略或在管理其增長和擴展運營方面遇到困難的風險；Tevogen 可能無法開發和維持有效內部控制的風險；未能實現 Tevogen 的商業化和發展計劃以及識別和實現額外機會的風險，這可能受到競爭、Tevogen 經濟增長和管理增長的能力以及招聘和留住關鍵員工等因素的影響；Tevogen 可能未能跟上快速的技術發展，以提供新的創新產品和服務，或在不成功的新產品和服務上進行大量投資的風險；Tevogen 需要籌集額外資金以充分實現其商業計劃的風險；與開發、許可或收購新療法相關的風險；與 Tevogen 業務相關的監管訴訟或程序的風險；在執行、成本和完成臨牀前研究和臨牀試驗中固有的不確定性；與監管審查、批准和商業開發相關的風險；與知識產權保護相關的風險；Tevogen 有限的運營歷史；以及在 Tevogen 的年度報告 10-K 表格及後續向 SEC 提交的文件中討論或引用的那些因素。</p>
<p>您不應對前瞻性聲明過於依賴，這些聲明僅在作出時有效。Tevogen 沒有義務更新任何前瞻性聲明，除非法律要求。</p>
<p><strong>聯繫方式</strong></p>
<p>Tevogen Bio 通訊部</p>
<p>電話：1 877 TEVOGEN，分機 701</p>
<p>Communications@Tevogen.com</p>
<p>與本公告相關的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/a79913bb-5354-496c-911d-2f8215cad958 獲取。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qRXhOU00zTXpNek5EUTRJekl5T0RrNU1UYz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qRXhOU00zTXpNek5EUTRJekl5T0RrNU1UYz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGYzMTg2N2UtYjE1ZC00MTMxLThmMmMtNzhkZDNlY2UwODczLTEzMDE0NjctMjAyNS0xMi0yMi1lbg==/tiny/Tevogen-Bio-Inc.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGYzMTg2N2UtYjE1ZC00MTMxLThmMmMtNzhkZDNlY2UwODczLTEzMDE0NjctMjAyNS0xMi0yMi1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

TVGN

<p>Tevogen Bio Holdings Inc. 的首席執行官 Ryan Saadi 博士向支持弱勢社區的非營利組織 SRLC USA 捐贈了 230,000 股股份。該捐贈符合美國證券交易委員會第 144 條規則，Saadi 博士沒有獲得任何收益。Tevogen 專注於利用人工智能和 T 細胞療法提供可負擔的醫療解決方案。該公司旨在通過高效的醫療模型推動可持續創新，擴大患者的醫療獲取渠道</p>

<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/a79913bb-5354-496c-911d-2f8215cad958/ryan-board-room-b.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/a79913bb-5354-496c-911d-2f8215cad958/ryan-board-room-b.png"/></p>
<p>WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 shares of Tevogen common stock to SRLC USA, a United Nations-recognized 501(c)(3) nonprofit organization dedicated to serving underserved communities.</p>
<div class="lb-trans"><p>新澤西州沃倫，2025 年 12 月 22 日（GLOBE NEWSWIRE）—— Tevogen（“Tevogen Bio Holdings Inc.” 或 “公司”）（納斯達克：TVGN）今天宣佈，其創始人兼首席執行官 Ryan Saadi 博士向 SRLC USA 捐贈了 230,000 股 Tevogen 普通股，該組織是一個獲得聯合國認可的 501(c)(3) 非營利組織，致力於服務弱勢社區。</p>
</div><p>“Education is one of the most powerful long-term investments we can make in building healthier, more equitable societies,” said Dr. Saadi. “I’m pleased to support an organization that is deeply committed to uplifting underserved communities through meaningful, measurable action.”</p>
<div class="lb-trans"><p>“教育是我們在建設更健康、更公平的社會中可以進行的最有力的長期投資之一，” Saadi 博士説。“我很高興能夠支持一個致力於通過有意義、可衡量的行動來提升弱勢社區的組織。”</p>
</div><p>The donation was conducted in accordance with SEC Rule 144 and Dr. Saadi will not receive any proceeds from the disposal of the securities.</p>
<div class="lb-trans"><p>此次捐贈是根據 SEC 第 144 條規則進行的，Saadi 博士將不會從證券處置中獲得任何收益。</p>
</div><p><strong>About Tevogen</strong></p>
<div class="lb-trans"><p><strong>關於 Tevogen</strong></p>
</div><p>Tevogen is a next-generation, socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages industry-leading artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and strategic engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.</p>
<div class="lb-trans"><p>Tevogen 是一家基於可負擔性、效率和科學嚴謹原則構建的下一代社會整合醫療企業。該公司利用行業領先的人工智能和精準 T 細胞治療平台，以患者為中心並注重成本的運營模式，以及與全球技術領導者的戰略合作，支持在多個治療領域開發先進的、拯救生命的療法和可擴展的解決方案，以改善更廣泛的醫療保健系統。</p>
</div><p>Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. The Tevogen Bio pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.</p>
<div class="lb-trans"><p>Tevogen Bio 是公司的主要項目，已完成一項概念驗證臨牀試驗，展示了其單 HLA 限制、基因未修飾的異體 T 細胞的潛力。Tevogen Bio 的產品線涵蓋病毒學、腫瘤學和神經學，基於公司的專有 ExacTcell™平台構建。</p>
</div><p>Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.</p>
<div class="lb-trans"><p>Tevogen.AI 旨在通過加速靶點檢測、幫助降低失敗率以及通過專有預測技術支持優化臨牀試驗設計來改變藥物開發。該平台利用來自領先技術提供商（包括微軟和 Databricks）的雲和數據服務，以推進其長期目標，即預測任何給定蛋白質-HLA 組合的蛋白質組，從而實現快速且成本高效的治療發現。</p>
</div><p>Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.</p>
<div class="lb-trans"><p>Tevogen 正在探索未來的戰略舉措，可能包括國內仿製藥、生物類似藥、醫療設備和創新保險解決方案，以服務醫療提供者。這些項目共同反映了 Tevogen 的使命，即通過更快、更高效和更公平的醫療模式推動可持續創新，擴大患者的獲取渠道。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.</p>
<div class="lb-trans"><p>本新聞稿包含某些前瞻性聲明，包括但不限於與 Tevogen 的研究和製造能力的計劃、未來增長的預期、對醫療保健和生物製藥行業的預期，以及 Tevogen 對其產品候選者在治療傳染病和癌症方面的開發、潛在益處和患者獲取的預期。前瞻性聲明有時可以通過 “可能”、“可以”、“將”、“期望”、“預期”、“可能”、“潛在”、“目標”、“機會”、“項目”、“相信”、“未來” 等詞語及其反義詞來識別。這些聲明基於管理層截至本新聞稿日期的期望、假設、估計、預測和信念，並受到多種因素的影響，這些因素涉及已知和未知的風險、延遲、不確定性以及其他不在公司控制範圍內的因素，可能導致公司的實際結果、表現或成就與這些前瞻性聲明所表達或暗示的結果、表現或其他期望存在重大差異。</p>
</div><p>Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.</p>
<div class="lb-trans"><p>可能導致實際結果、表現或成就與前瞻性聲明所表達或暗示的結果存在差異的因素包括但不限於：Tevogen 所競爭市場的變化，包括其競爭格局、技術演變或監管變化；國內和全球經濟狀況的變化；Tevogen 可能無法執行其增長戰略或在管理其增長和擴展運營方面遇到困難的風險；Tevogen 可能無法開發和維持有效內部控制的風險；未能實現 Tevogen 的商業化和發展計劃以及識別和實現額外機會的風險，這可能受到競爭、Tevogen 經濟增長和管理增長的能力以及招聘和留住關鍵員工等因素的影響；Tevogen 可能未能跟上快速的技術發展，以提供新的創新產品和服務，或在不成功的新產品和服務上進行大量投資的風險；Tevogen 需要籌集額外資金以充分實現其商業計劃的風險；與開發、許可或收購新療法相關的風險；與 Tevogen 業務相關的監管訴訟或程序的風險；在執行、成本和完成臨牀前研究和臨牀試驗中固有的不確定性；與監管審查、批准和商業開發相關的風險；與知識產權保護相關的風險；Tevogen 有限的運營歷史；以及在 Tevogen 的年度報告 10-K 表格及後續向 SEC 提交的文件中討論或引用的那些因素。</p>
</div><p>You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.</p>
<div class="lb-trans"><p>您不應對前瞻性聲明過於依賴，這些聲明僅在作出時有效。Tevogen 沒有義務更新任何前瞻性聲明，除非法律要求。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>聯繫方式</strong></p>
</div><p>Tevogen Bio Communications</p>
<div class="lb-trans"><p>Tevogen Bio 通訊部</p>
</div><p>T: 1 877 TEVOGEN, Ext 701</p>
<div class="lb-trans"><p>電話：1 877 TEVOGEN，分機 701</p>
</div><p>Communications@Tevogen.com</p>
<div class="lb-trans"><p>Communications@Tevogen.com</p>
</div><p>A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a79913bb-5354-496c-911d-2f8215cad958</p>
<div class="lb-trans"><p>與本公告相關的照片可在 https://www.globenewswire.com/NewsRoom/AttachmentNg/a79913bb-5354-496c-911d-2f8215cad958 獲取。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeE5qRXhOU00zTXpNek5EUTRJekl5T0RrNU1UYz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYxNjExNSM3MzMzNDQ4IzIyODk5MTc="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGYzMTg2N2UtYjE1ZC00MTMxLThmMmMtNzhkZDNlY2UwODczLTEzMDE0NjctMjAyNS0xMi0yMi1lbg==/tiny/Tevogen-Bio-Inc.png" alt="" original-src="https://ml.globenewswire.com/media/NGYzMTg2N2UtYjE1ZC00MTMxLThmMmMtNzhkZDNlY2UwODczLTEzMDE0NjctMjAyNS0xMi0yMi1lbg==/tiny/Tevogen-Bio-Inc.png"/></p>

Tevogen 首席執行官捐贈股份以支持貧困兒童的教育 | TVGN 股票新聞